Oak Thistle LLC Invests $1.74 Million in Cencora, Inc. $COR

Oak Thistle LLC bought a new position in shares of Cencora, Inc. (NYSE:COR) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 5,551 shares of the company’s stock, valued at approximately $1,735,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in COR. Atlantic Edge Private Wealth Management LLC grew its stake in shares of Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares during the last quarter. Vermillion & White Wealth Management Group LLC boosted its stake in Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after purchasing an additional 43 shares in the last quarter. Caldwell Trust Co purchased a new stake in Cencora during the 2nd quarter worth approximately $46,000. Capital A Wealth Management LLC increased its stake in Cencora by 3,975.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock valued at $49,000 after purchasing an additional 159 shares in the last quarter. Finally, Twin Peaks Wealth Advisors LLC purchased a new position in shares of Cencora in the second quarter worth $52,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Stock Up 0.4%

Cencora stock opened at $343.02 on Thursday. The business’s 50-day moving average price is $345.49 and its 200 day moving average price is $312.47. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. The firm has a market cap of $66.54 billion, a price-to-earnings ratio of 43.15, a price-to-earnings-growth ratio of 1.62 and a beta of 0.63. Cencora, Inc. has a 52 week low of $223.92 and a 52 week high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, sell-side analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were given a dividend of $0.60 per share. This is a boost from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio (DPR) is 30.19%.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total value of $1,868,397.44. Following the completion of the transaction, the chief executive officer owned 65,746 shares of the company’s stock, valued at approximately $24,105,113.44. The trade was a 7.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 10.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Barclays assumed coverage on Cencora in a research report on Monday, December 8th. They issued an “overweight” rating and a $400.00 target price on the stock. Mizuho raised their price objective on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Robert W. Baird set a $392.00 price target on shares of Cencora in a report on Tuesday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $373.25.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.